arrow
S

Sara M. Federico

St. Jude Children's Research Hospital
H指数:23
被引数:2,506

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma

ESFT13:一项评估在标准化疗基础上增加窗口期治疗和维持治疗以治疗高危尤因肉瘤的II期研究

2025-09-040
OAAI
International neuroblastoma risk group consortium: a model of networking for rare cancers
2025-08-250
OAAI
Grading of Recommendations Assessment, Development, and Evaluation and Confidence in Network Meta-Analysis showed moderate to substantial concordance in the evaluation of certainty of the evidence

GRADE(Grading of Recommendations Assessment, Development, and Evaluation)和Network Meta-Analysis中的置信度评估在证据确定性评价方面显示出中度至高度的一致性。

2025-05-050
PRE
Genomic profiling of circulating tumor DNA for childhood cancers
LEUKEMIA
IF13.4
2024-11-100
PRE
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
2024-03-010
OAAI
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2023-09-016
OAAI
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
2021-08-1911
OA
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

talazoparib和伊立替康联合或不联合替莫唑胺在患有复发性或难治性实体恶性肿瘤的儿童和年轻人中的I期试验

2020-09-0144
PREAI